Physician profile
Dmitriy Vaysman
NPI 1245231232
$2,658.34
in general payments reported to CMS, 2019-2025
36 companies · $811 in 2025
The $811 reported for 2025 was more than what 84% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $140 · 2021: $119 · 2022: $244 · 2023: $728 · 2024: $400 · 2025: $811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,938.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $307.53 | 2020-2025 | |
| Axsome Therapeutics, INC. | $238.45 | 2025 | Sunosi |
| Corium, LLC | $216.70 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $172.67 | 2022-2025 | Qelbree, Qelbree |
| Inspire Medical Systems, INC. | $153.23 | 2023 | Inspire |
| Depuy Synthes Sales INC. | $147.79 | 2025 | Crosstie |
| Ucb, INC. | $134.64 | 2022-2025 | Fintepla, Briviact, Nayzilam |
| Baxter Healthcare | $124.50 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Glaxosmithkline, LLC. | $123.38 | 2019-2024 | Nucala |
| Xeris Pharmaceuticals, INC. | $103.22 | 2021-2024 | Gvoke Hypopen |
| Ironshore Pharmaceuticals INC. | $97.62 | 2023-2024 | Jornay Pm |
| Covis Pharma Gmbh | $78.38 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $69.47 | 2023-2025 | Dupixent |
| Sunovion Pharmaceuticals INC. | $66.77 | 2019 | |
| Biomarin Pharmaceutical INC. | $61.95 | 2023-2025 | Voxzogo 1.2mg |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $52.61 | 2025 | Smartvest |
| Philips North America LLC | $48.26 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $45.39 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $42.24 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $41.73 | 2023-2024 | Strensiq, Ultomiris |
| Mirum Pharmaceuticals, INC. | $40.78 | 2023-2025 | Livmarli, Cholbam |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.20 | 2019-2020 | |
| Grifols USA, LLC | $29.59 | 2025 | Xembify |
| Zogenix INC. | $22.01 | 2021 | |
| Vertical Pharmaceuticals, LLC | $20.74 | 2019 | |
| Dexcom, INC. | $19.36 | 2023 | Dexcom G6 Transmitter |
| Insulet Corporation | $18.66 | 2024 | Omnipod |
| Acadia Pharmaceuticals INC | $18.32 | 2024 | Daybue |
| Azurity Pharmaceuticals, INC. | $18.24 | 2025 | Triptodur |
| Phadia US INC. | $18.24 | 2023 | Immunocap |
| Abbvie INC. | $16.81 | 2025 | |
| Arbor Pharmaceuticals, INC. | $16.77 | 2019 | |
| Novo Nordisk INC | $16.18 | 2024 | Rivfloza |
| Takeda Pharmaceuticals U.S.A., INC. | $15.30 | 2024 | Eohilia |
| Greenwich Biosciences, INC. | $13.96 | 2021 | |
| Janssen Biotech, INC. | $13.65 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitriy Vaysman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.